GLK 10
Alternative Names: GLK-10Latest Information Update: 01 Feb 2024
At a glance
- Originator Glykos
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 28 Jan 2024 GLK 10 is available for licensing as of 28 Jan 2024. https://www.glykos.fi/ (Glkos pipeline; January 2024)
- 27 Jan 2024 Early research in Solid tumours in Finland (Parenteral) (Glykos pipeline; January 2024)